Joël Besse

Response Pharmaceuticals is developing its lead asset, RDX-002, a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. All programs are in Phase 2 clinical development. Our initial focus is on helping underserved patient populations taking antipsychotic medications for disabling mental illnesses to combat weight gain and metabolic dysregulation associated with these treatments. Antipsychotic-induced weight gain (AIWG) is a drug-induced epidemic within the already vulnerable population of patients with severe mental illness, and is contributing to a growing mortality gap between people with mental illness and the general population. Additionally, RDX-002 is being evaluated in other settings in which clinically significant weight gain and/or adverse metabolic changes are prevalent.

Longlive is a health-tech company building AI-driven solutions that improve clinical decision-making, early intervention and preventative health at scale. We operate at the intersection of life sciences, med-tech and digital health, transforming how clinicians and individuals access clarity, confidence and personalised guidance. Our mission is to close critical gaps in care pathways — from compression therapy to chronic disease prevention — by combining intelligent data, clinical insight and wearable technology into tools that support safer, earlier and more consistent decision-making. Our flagship innovation is the AI-Guided Clinical Compression Assistant, designed to help non-specialist clinicians start safe, guideline-aligned compression therapy in under two minutes. This addresses a long-standing clinical need, where up to 80% of eligible patients never receive appropriate compression in primary care due to uncertainty and lack of confidence. By reducing this friction, we aim to improve healing outcomes while supporting more consistent utilisation of evidence-based therapy across venous, oedema and wound-care pathways. Alongside our clinical AI work, the Longlive platform supports preventative health and corporate wellbeing through intelligent insights derived from wearable data, personalised coaching, early risk detection and behaviour-change support. Our broader goal is to empower individuals and organisations with tools that promote healthier lives and reduce avoidable healthcare burden. We are guided by a simple principle: technology should enable better decisions — for clinicians, for patients, and for and for the health systems that serve them. If youre exploring advancements in clinical decision support, wound care innovation, preventative health or digital transformation, we’d love to connect.

We make and sell brain imaging systems showing neural activity called magnetoencephalographs (MEG). We democratize the use of MEG, using a space technology, to effectively detect brain defects and improve brain cares

Ramify réinvente la gestion de patrimoine en offrant aux particuliers laccès à des solutions dignes des plus grandes banques privées. Gestion pilotée, immobilier, private equity ou encore solutions d’épargne : notre approche allie expertise, diversification et innovation pour bâtir un avenir financier à la hauteur de vos ambitions.

The future of recombinant protein bioproduction.

Deciphering white matter to enable better care

QurCan Therapeutics (formerly Nanology Labs Inc) is a biotechnology company using advanced nanoparticle drug-delivery technology to unleash the immense potential of next-generation biological and genetic medicine and deliver life-changing therapeutics. QurCans next generation nanoparticle platform, TERP, enables tissue-selective delivery of nucleotides and biological therapeutics to extra-hepatic sites, including brain and spleen. TERP technology is a breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine that will make a difference to patients with a wide range of unmet medical needs.

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.

Response Pharmaceuticals is developing its lead asset, RDX-002, a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. All programs are in Phase 2 clinical development. Our initial focus is on helping underserved patient populations taking antipsychotic medications for disabling mental illnesses to combat weight gain and metabolic dysregulation associated with these treatments. Antipsychotic-induced weight gain (AIWG) is a drug-induced epidemic within the already vulnerable population of patients with severe mental illness, and is contributing to a growing mortality gap between people with mental illness and the general population. Additionally, RDX-002 is being evaluated in other settings in which clinically significant weight gain and/or adverse metabolic changes are prevalent.

At Save the Children Global Ventures we are working with technology start-ups and investors to give children a better world. Our work complements traditional grant-making and philanthropy with an increased use of innovative financing instruments, including loans, guarantees and blended finance funds.

Longlive is a health-tech company building AI-driven solutions that improve clinical decision-making, early intervention and preventative health at scale. We operate at the intersection of life sciences, med-tech and digital health, transforming how clinicians and individuals access clarity, confidence and personalised guidance. Our mission is to close critical gaps in care pathways — from compression therapy to chronic disease prevention — by combining intelligent data, clinical insight and wearable technology into tools that support safer, earlier and more consistent decision-making. Our flagship innovation is the AI-Guided Clinical Compression Assistant, designed to help non-specialist clinicians start safe, guideline-aligned compression therapy in under two minutes. This addresses a long-standing clinical need, where up to 80% of eligible patients never receive appropriate compression in primary care due to uncertainty and lack of confidence. By reducing this friction, we aim to improve healing outcomes while supporting more consistent utilisation of evidence-based therapy across venous, oedema and wound-care pathways. Alongside our clinical AI work, the Longlive platform supports preventative health and corporate wellbeing through intelligent insights derived from wearable data, personalised coaching, early risk detection and behaviour-change support. Our broader goal is to empower individuals and organisations with tools that promote healthier lives and reduce avoidable healthcare burden. We are guided by a simple principle: technology should enable better decisions — for clinicians, for patients, and for and for the health systems that serve them. If youre exploring advancements in clinical decision support, wound care innovation, preventative health or digital transformation, we’d love to connect.

We make and sell brain imaging systems showing neural activity called magnetoencephalographs (MEG). We democratize the use of MEG, using a space technology, to effectively detect brain defects and improve brain cares

Ramify réinvente la gestion de patrimoine en offrant aux particuliers laccès à des solutions dignes des plus grandes banques privées. Gestion pilotée, immobilier, private equity ou encore solutions d’épargne : notre approche allie expertise, diversification et innovation pour bâtir un avenir financier à la hauteur de vos ambitions.